- Home
- BCRX
as 01-17-2025 4:00pm EST
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 1.5B | IPO Year: | 1994 |
| Target Price: | $15.17 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.03 - $8.88 | Next Earning Date: | 02-24-2025 |
| Revenue: | $412,579,000 | Revenue Growth: | 29.92% |
| Revenue Growth (this year): | 38.01% | Revenue Growth (next year): | 19.04% |
Stock Insider Trading Activity of BioCryst Pharmaceuticals Inc. (BCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hutson Nancy J | BCRX | Director | Dec 13 '24 | Sell | $7.54 | 7,000 | $52,780.00 | 86,638 |
Latest BioCryst Pharmaceuticals Inc. News
BCRX Breaking Stock News: Dive into BCRX Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
BioCryst price target raised to $12 from $10 at Evercore ISI
Simply Wall St.
8 days ago
Exploring High Growth Tech Stocks In January 2025
MT Newswires
9 days ago
BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises
GlobeNewswire
9 days ago
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
GlobeNewswire
12 days ago
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
13 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
23 days ago
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%
Simply Wall St.
a month ago
High Growth Tech Stocks To Watch In December 2024
Compare BCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCRX BioCryst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.